Glaxo launches late-stage study of mepolizumab in patients with nasal polyps
Seeking Alpha
Published Jun 27, 2017 02:16PM ET
Glaxo launches late-stage study of mepolizumab in patients with nasal polyps
- GlaxoSmithKline (GSK -0.4%) initiates a Phase 3 clinical trial, SYNAPSE, assessing mepolizumab, an interleukin-5 (IL-5) antagonist, for the treatment of nasal polyps, a chronic inflammatory disorder that leads to the obstruction of the nasal passages from soft tissue growth.
- The 400-subject study will evaluate the safety and efficacy of 100 mg of mepolizumab, administered every four weeks via pre-filled syringe, for 52 weeks on top of standard-of-care treatment (intranasal corticosteroids).
- Mepolizumab is currently marketed under brand name NUCALA for the treatment of severe asthma.
- Now read: 'Major' Reprieve Number Two: Another Stumble For GlaxoSmithKline's Advair Blockbuster Generic US Competition
Original article
Get The News You Want
Written By: Seeking Alpha
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.